Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2000
04/20/2000WO2000003994A3 Biphenylsulfonyl-substituted imidazole derivatives, their preparation process, their use as a drug or diagnostic agent and drug containing them
04/20/2000WO2000003749A3 Method for regulating hair growth
04/20/2000WO2000003746A3 Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
04/20/2000WO2000003745A3 Polysaccharide vaccine for staphylococcal infections
04/20/2000WO2000003742A3 Solid oral dosage form comprising a combination of metformin and glibenclamide
04/20/2000WO2000003737A3 Water-soluble drugs and methods for their production
04/20/2000WO2000003689A3 Skin and tissue care and/or treatment agent
04/20/2000WO2000003684A3 Soy formulations and their use for promoting health
04/20/2000WO2000003004A3 Presenilin 2 specific ribozyme
04/20/2000WO2000002519A3 Utilization of derivatives of tetrahydropyridines (or 4-hydroxypiperidines)-butylazols in the preparation of a medicament for the treatment of pain
04/20/2000WO1999066958A3 Use of a compound having affinity for the benzodiazepine mitochondrial receptor in cancer therapy
04/20/2000WO1999066917A3 Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid
04/20/2000WO1999066913A3 Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein
04/20/2000WO1999066037A3 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
04/20/2000WO1999065571A3 Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
04/20/2000WO1999064050A9 Novel potassium channel drugs and their uses
04/20/2000WO1999064046A9 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-ht3 receptors
04/20/2000WO1999064000A9 Novel therapeutic agents that modulate neurokinin receptors
04/20/2000WO1999063981A3 Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
04/20/2000WO1999060986A3 Apoptosis modulators that interact with the huntington's disease gene
04/20/2000WO1999058658A3 Expression vectors for stimulating an immune response and methods of using the same
04/20/2000WO1999057266A3 Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction)
04/20/2000WO1999048868A9 Heterocyclic classes of compounds for the modulating tyrosine protein kinase
04/20/2000WO1999037293A3 Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders
04/20/2000DE19950327A1 Use of carotenoid ester compounds, especially derived from lutein and zeaxanthin, in prevention and treatment of eye disorders, especially age-related macular degeneration and cataract
04/20/2000DE19848303A1 Stable combination of 14,17-over-bridged steroid gestagen and cyclodextrin compound, useful for treating climacteric disorders or for contraception
04/20/2000DE19848130A1 Cholesteric liquid crystalline polymer especially in pigment form, useful as UV filters in cosmetic and pharmaceutical preparations
04/20/2000DE19847970A1 Stable concentrated liquid formulation of inhalable drug, e.g. formoterol or salbutamol, in solution or suspension medium, used after dilution for treatment of respiratory disorders by inhalation
04/20/2000DE19847969A1 Stable liquid formulation of formoterol in solution or suspension medium, used after dilution for treatment of asthma by inhalation
04/20/2000DE19847968A1 Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit.
04/20/2000DE19847823A1 New 3-(Hetero)aryl-5-aminosulfonyl-1,2,4-thiadiazole derivatives useful as inhibitors of IL-1beta production in treatment of e.g. leukemia, septic shock, hepatitis, AIDS and diseases of locomotor system
04/20/2000DE19847715A1 Treatment of schizophrenia symptoms without side effects, by transdermal administration of nicotine or its salt
04/20/2000DE19847691A1 Verwendung von Piperonal als entzündungshemmender Zusatz zu Kosmetika und Arzneimitteln Use of piperonal as anti-inflammatory additive to cosmetics and pharmaceuticals
04/20/2000DE19847618A1 Production of solid dosage forms, used for e.g. pharmaceuticals or insecticides, by preparation of plastic mixture from polymeric binder and active agent under controlled conditions
04/20/2000DE19847137A1 Use of 9.10-dihydro-9-oxa-10-phospha-phenenthrene 10-oxide as antioxidant, e.g. for polymers, fats, oils, functional fluids, foods, animal feeds, pharmaceuticals and cosmetics
04/20/2000DE19847114A1 Use of proteolytic enzymes to modulate hyperactive T cells, especially for symptomatic treatment of immune-mediated inflammatory diseases, e.g. multiple sclerosis, diabetes, arthritis or glomerulonephritis
04/20/2000DE19846517A1 New 3-phenyl-4-hydroxy-2-pyrone derivatives useful as pesticides, herbicides and fungicides
04/20/2000DE19846514A1 New arylmethyl and heterocyclylmethyl substituted heteroaryl-indazole derivatives useful in treatment of cardiovascular, ischemic and urogenital disorders
04/20/2000DE19845405A1 Arylsubstituierte Propanolaminderivate und deren Verwendung Aryl-substituted Propanolaminderivate and their use
04/20/2000DE19845372A1 Verwendung von Katecholderivaten als Proteinaseninhibitoren Using catechol as proteinase inhibitors
04/20/2000DE19845278A1 Retard tablet of antiepileptic agent losigamone, containing combination of retarding and disintegrating agents to provide appropriate slow release from tablet of acceptable size
04/20/2000DE19843793A1 Substituierte Benzamide Substituted benzamides
04/20/2000CA2653503A1 The use of ara as a supplement for a lactating woman
04/20/2000CA2350897A1 Prevention and treatment of migraine and other recurrent headaches using leukotriene ltd4 receptor blocker drugs
04/20/2000CA2347653A1 Novel cell signaling polypeptides and nucleic acids
04/20/2000CA2347519A1 An agent for treating ophthalmopathy
04/20/2000CA2347225A1 Pharmaceutical formulations for use in estrogen deprivation syndrome
04/20/2000CA2347192A1 Pharmaceutical combination of ibuprofen-lysine and domperidone for treating migraine
04/20/2000CA2347121A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein
04/20/2000CA2347092A1 1,2-disubstituted cyclopropanes
04/20/2000CA2346867A1 Use of ophthalmic composition comprising vitamin a and vitamin e
04/20/2000CA2346848A1 Cream cleanser with high levels of emollients and glycerin
04/20/2000CA2346813A1 Method and composition for treating and preventing tuberculosis
04/20/2000CA2346773A1 Methods for treating multiple sclerosis
04/20/2000CA2346729A1 Ureidopiperidine derivatives as selective human nk3 receptor antagonists
04/20/2000CA2346698A1 Novel heterocyclyl-methyl-substituted pyrazoles
04/20/2000CA2346693A1 Pregnane glucuronides
04/20/2000CA2346689A1 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
04/20/2000CA2346542A1 Imidazo-benzazepines having cardiovascular, antitumor, antiinfective and antiinflammatory activity
04/20/2000CA2346464A1 Peripherally acting anti-pruritic opiates
04/20/2000CA2346433A1 New processes for producing .beta.-alanine derivative
04/20/2000CA2346421A1 Propofol-based anesthetic and method of making same
04/20/2000CA2346414A1 Imidazo-isoquinoline compounds, their compositions and uses
04/20/2000CA2346334A1 Composition for treating or preventing ischemia reperfusion injury
04/20/2000CA2346329A1 Hydrogels and water soluble polymeric carriers for drug delivery
04/20/2000CA2346307A1 Formulations of fexofenadine
04/20/2000CA2346228A1 Composition and method for treating allergic diseases
04/20/2000CA2346227A1 Composition and method for treating allergic diseases
04/20/2000CA2346155A1 Enzymatic synthesis of ssdna
04/20/2000CA2346038A1 Methods for inhibiting bone resorption
04/20/2000CA2346036A1 Methods for regulating bone formation
04/20/2000CA2346031A1 Methods for stimulating bone formation
04/20/2000CA2345885A1 Bone morphogenic protein-induced genes and polypeptides, and their use in diagnostic and therapeutic methods
04/20/2000CA2345132A1 Oral combination of lufenuron and nitenpyram against fleas
04/20/2000CA2344696A1 Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid
04/20/2000CA2344694A1 Benzazine derivatives as phosphodiesterase 4 inhibitors
04/20/2000CA2342623A1 Heterocyclylaminomethyloxazolidinones as antibacterials
04/20/2000CA2315375A1 A dried or frozen pharmaceutical preparation containing a class iii antiarrhythmic compound
04/20/2000CA2314004A1 Matrix-remodeling genes
04/20/2000CA2311937A1 Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis
04/19/2000EP0994119A1 Stereoselective process for the preparation of the 22R epimer of budesonide
04/19/2000EP0994115A2 Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof
04/19/2000EP0994113A2 7-Aminopyrido(2,3-d)-pyrimidine derivatives for treatment of bronchial asthma
04/19/2000EP0994111A1 Tetrahydrofuran derivatives
04/19/2000EP0994110A1 Sulphonamide derivatives
04/19/2000EP0994107A1 5-Arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds
04/19/2000EP0994105A2 2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists
04/19/2000EP0994104A1 Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
04/19/2000EP0994102A1 Cyclic derivatives with a cycloalkylenic chain, process for their preparation and pharmaceutical compositions containing them
04/19/2000EP0994093A1 Polyhydroxyphenol derivatives and preventive and therapeutic agents for bone and cartilage diseases containing the same
04/19/2000EP0993831A2 Compounds and compositions for delivering active agents
04/19/2000EP0993830A2 New stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
04/19/2000EP0993829A1 Transdermal preparation containing serotonin receptor antagonist
04/19/2000EP0993825A2 Urea containing composition and its cosmetic and dermatologic use
04/19/2000EP0993822A1 Ceramide production-accelerating agent
04/19/2000EP0993468A1 Compositions and methods for activating genes of interest
04/19/2000EP0993461A1 New quinoxaline dione derivatives, the production thereof and use of the same in medicaments
04/19/2000EP0993460A1 Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
04/19/2000EP0993459A1 Compounds useful for inhibition of farnesyl protein transferase
04/19/2000EP0993458A1 3-benzylpiperidine